Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Longitudinal Study to Evaluate an Extracellular Matrix (MatriStem®) for the Treatment of Diabetic Foot Ulcers (M-S-DFU-RCT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02750280
Recruitment Status : Completed
First Posted : April 25, 2016
Last Update Posted : April 25, 2016
Sponsor:
Collaborator:
ACell Inc.
Information provided by (Responsible Party):
Oscar M. Alvarez, PhD, Calvary Hospital, Bronx, NY

Brief Summary:
This ia a prospective controlled longitudinal study to evaluate the effects of MatriStem® plus standard local wound care versus standard local wound care alone in the treatment of diabetic foot ulcers (DFUs), as assessed by incidence of complete wound healing by 16 weeks and ulcer recurrence with a 2 year follow-up.

Condition or disease Intervention/treatment Phase
Neuropathic Diabetic Foot Ulcer Device: MatriStem® [Urinary Bladder Matrix (UBM)] Device: Mepilex® [Silicone foam dressing] Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 17 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Prospective, Randomized, Controlled, Longitudinal Study Using Repeated Measures Design to Evaluate a Porcine Urinary Bladder-Derived Extracellular Matrix (MatriStem®) in the Management of Diabetic Foot Ulcers
Study Start Date : June 2015
Actual Primary Completion Date : December 2015
Actual Study Completion Date : December 2015

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Urinary Bladder matrix (UBM)
UBM covered with silicone foam dressing plus total contact cast
Device: MatriStem® [Urinary Bladder Matrix (UBM)]
Porcine derived urinary bladder extracellular matrix
Other Name: MatriStem

Active Comparator: Standard Care
Silicone foam dressing plus total contact cast
Device: Mepilex® [Silicone foam dressing]
primary wound dressing
Other Name: Mepilex




Primary Outcome Measures :
  1. Incidence of wound healing [ Time Frame: 16 weeks ]

Secondary Outcome Measures :
  1. Incidence of ulcer recurrence [ Time Frame: 1 year ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Male and female subjects 18-85 years of age with diabetes mellitus (type 1 or type 2)
  2. Subject's foot ulcer is on the plantar surface of the foot.
  3. DFU has not healed after more than2 months of SOC treatment administered
  4. Subject's ulcer must be Wagner type 1 or 2 (uninfected, extending through the dermis and into subcutaneous tissue or granulating but without exposure of tendon, bone, or joint capsule.
  5. Subject's wound is free of necrotic debris (post debridement) and clinical infection, should be comprised of healthy, vascular tissue.
  6. Subject's Ankle-Brachial Index (ABI) by Doppler method is ≥ 0.7
  7. The subject has adequate circulation to the foot to allow for healing. This must be demonstrated by methods described in section 5.1
  8. Subject's diabetes is under control as determined by the Investigator
  9. Study subject must be reliable, responsible and able to visit the clinic weekly for the full 16 week period. The subject is willing and able to tolerate TCC. Subject is willing to comply with the monthly follow-up regimen for 32 weeks (8 months) The subject is able to return to the clinic if ulcer recurrence occurs
  10. Subject or his/her legal representative has read and signed the Institutional Review Board (IRB) approved Informed Consent form before treatment
  11. No active malignancy except non-melanoma skin cancer

Exclusion Criteria:

  1. Subject has clinical evidence of gangrene on any part of the affected foot
  2. Subject has a Wagner type 3 or greater ulceration
  3. The subject's ulcer is due to a non-diabetic etiology, Ulcers of arterial, venous stasis, pressure, radiation, traumatic, rheumatoid, vasculitis, collagen vascular disease, or other non-diabetic etiologies
  4. Subject has a known sensitivity to bovine or porcine derived devices
  5. Subject has one or more medical condition(s) including renal, hepatic, hematological, neurologic, or immune disease that in the opinion of the Investigator would make the subject an inappropriate candidate for this wound healing study
  6. Subject has or has had a malignant disease (other than cutaneous epithelioma) not in remission
  7. Subject is receiving oral or parenteral corticosteroids, immunosuppressive or cytotoxic agents, or is anticipated to require such agents during the course of the study
  8. Subject has chronic osteomyelitis as determined by high resolution ultrasonography
  9. Subject's ulcer is infected or accompanied by active cellulitis as determined by the Investigator
  10. Subject has any condition(s) that seriously compromises the subject's ability to complete the study
  11. Subject is pregnant or lactating at the time of treatment
  12. Subject has received growth factor therapy (e.g. autologous platelet-rich plasma gel, bacaplermin, bilayered cell therapy, dermal substitute, extracellular matrix) within two weeks of enrollment. If Santyl or any other collagenase is used, a subject must have a washout period of 2 weeks before MatriStem® can be applied.
  13. Subject is currently receiving or has received radiation or chemotherapy within 3 months of randomization
  14. Subject has a history of alcohol or drug abuse
  15. Subject allergic to a broad spectrum of primary & secondary dressing materials, including occlusive dressings and the adhesives on such dressings.
  16. Subject is currently enrolled or participated within the previous 30 days of enrollment in another device, drug or biological trial.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02750280


Locations
Layout table for location information
United States, New York
Calvary Hospital Center for Curative and Palliative Wound Care
Bronx, New York, United States, 10461
Sponsors and Collaborators
Calvary Hospital, Bronx, NY
ACell Inc.
Investigators
Layout table for investigator information
Principal Investigator: oscar Alvarez, PhD Calvary Hospital Director, Center for curative and palliative wound care

Layout table for additonal information
Responsible Party: Oscar M. Alvarez, PhD, Director, Center for Curative & palliative Wound Care, Calvary Hospital, Bronx, NY
ClinicalTrials.gov Identifier: NCT02750280     History of Changes
Other Study ID Numbers: CA2014-002
First Posted: April 25, 2016    Key Record Dates
Last Update Posted: April 25, 2016
Last Verified: April 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Ulcer
Diabetic Foot
Foot Ulcer
Pathologic Processes
Diabetic Angiopathies
Vascular Diseases
Cardiovascular Diseases
Leg Ulcer
Skin Ulcer
Skin Diseases
Diabetes Complications
Diabetes Mellitus
Endocrine System Diseases
Diabetic Neuropathies
Foot Diseases